Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Optimi HealthOPTH +5.26%25 Debt-to-Equity is 1.86 as of Mar. 2026, which is 6100% above its 10-year median of 0.03. GuruFocus rates OPTH with a GF Score™ of 25/100 and a GF Value™ of $4.42 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 812 Drug Manufacturers companies, Optimi Health ranks worse than 94.83% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Optimi Health's Debt-to-Equity or its related term are showing as below:
OPTH'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.03 Max: 1.86
Current: 1.86
During the past 6 years, the highest Debt-to-Equity Ratio of Optimi Health was 1.86. The lowest was 0.01. And the median was 0.03.
OPTH's Debt-to-Equity is ranked worse than 94.83% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs OPTH: 1.86
Optimi Health (NAS:OPTH) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Optimi Health Debt-to-Equity Related Terms
Optimi Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Optimi Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Optimi Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Optimi Health Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Optimi Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Optimi Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Optimi Health (OPTH) has a Debt-to-Equity of 1.86 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Optimi Health and its competitors. This is 6100% above median its historical median of 0.03. Over the past decade, Optimi Health's Debt-to-Equity has ranged from 0.01 to 1.86. According to the industry distribution chart, Optimi Health ranks #770 out of 812 companies in the Drug Manufacturers industry, placing it in the top 94.8%.
Is Optimi Health's Debt-to-Equity too high?
Optimi Health's current Debt-to-Equity of 1.86 is 6100% above median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.86. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Optimi Health's value of 1.86 is 588.9% above this industry median. Based on the distribution chart, Optimi Health ranks #770 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Optimi Health has a GF Score™ of 25/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Optimi Health's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Optimi Health ranks #770 out of 812 companies for Debt-to-Equity. This places Optimi Health in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Optimi Health's value of 1.86 is 588.9% above this benchmark. Historically, Optimi Health's own Debt-to-Equity has ranged from 0.01 to 1.86 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 0.27, Optimi Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Optimi Health's current Debt-to-Equity of 1.86 is 588.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Optimi Health and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Optimi Health's current Debt-to-Equity is 1.86, which is 6100% above median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Optimi Health stock overvalued right now?
Based on GuruFocus' analysis, Optimi Health (OPTH) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.42, compared to a current price of $5.00 — trading 13.1% above its estimated fair value. The current Debt-to-Equity is 1.86, which is 6100% above median its 10-year median of 0.03 and 588.9% above the Drug Manufacturers industry median of 0.27. Optimi Health's overall GF Score™ is 25/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Optimi Health (OPTH), the current Debt-to-Equity is 1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Optimi Health (OPTH) Overvalued in 2026?
Based on GuruFocus' analysis, Optimi Health stock appears to be overvalued.
The current stock price of $5.00 is trading 13.1% above its estimated GF Value™ of $4.42.
GuruFocus considers Optimi Health to be Modestly Overvalued.
Key valuation signals for OPTH:
Debt-to-Equity: 1.86 (6100% above median its 10-year median of 0.03)
GF Value™: $4.42 vs. price of $5.00 (13.1% above fair value)
Industry Position: 588.9% above the Drug Manufacturers median (#770 of 812)
No single metric tells the full story. See the OPTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Optimi Health Corp operates in developing a vertically integrated Canadian functional mushroom brand that focuses on the health and wellness sector. The company has one reportable operating segment being that of the farming, processing, and distribution of raw mushroom biomass. It also intends to cultivate, extract, process, and distribute strains of fungi products at its facilities located in Princeton, British Columbia.
25GF Score
Get the complete analysis for OPTH
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OPTH has been successfully added to your 
